NMTC Q3 2026 Earnings Call Summary

1Key Financial Results and Metrics

Product Revenue: $2 million for Q3 2026, a 16% increase from $1.7 million in Q3 2025.

Orders: Total orders reached $2.7 million, representing a 43% year-over-year growth.

Gross Margin: Expanded to 59.9% from 53.9% year-over-year, attributed to a favorable product mix.

Net Loss: $2 million, or $0.23 per basic share, compared to a net loss of $1.5 million, or $0.19 per basic share, in the prior year.

Cash Position: Cash and cash equivalents decreased to $2 million from $6.6 million as of September 30, 2025.

Working Capital: $3.7 million as of June 30, 2026, down from $7.9 million in the previous year.

2Strategic Updates and Business Highlights

ISO Certification: Achieved ISO 13485 certification, enabling entry into international markets for the OneRF product lines.

Product Development: Continued progress on the OneRF Brain Ablation System and OneRF Trigeminal Neuralgia Ablation System, with significant clinical milestones reported, including a study published in the Journal of Neurosurgery.

StereoCED Drug Delivery System: Anticipated readiness for investigational human clinical studies by the end of September, with promising feedback from pharmaceutical companies.

BVNA System: Completed user design requirements and initiated preclinical testing, with plans for a 510(k) submission expected in the second half of 2027.

3Forward Guidance and Outlook

Revenue Guidance: Expected recognized revenue for fiscal year 2026 is between $9.2 million and $10.5 million, contingent on manufacturing and shipment timelines. Aggregate product orders are projected at approximately $11.2 million.

Manufacturing Expansion: Plans to qualify a second manufacturing site to increase capacity and reduce lead times, expected to come online in early 2027.

4Bad News, Challenges, or Points of Concern

Manufacturing Delays: Ongoing challenges with supplier lead times impacting the ability to fulfill orders, which may affect revenue realization.

Cash Burn: Significant decrease in cash reserves raises concerns about liquidity and operational sustainability.

Dependence on Partners: Reliance on Zimmer Biomet for distribution and market penetration may limit flexibility and speed in addressing market opportunities.

5Notable Q&A Insights

Supplier Issues: CEO Dave Rosa discussed lead times of up to six months and the impact of product mix changes on manufacturing efficiency.

International Market Strategy: Rosa emphasized the importance of ISO certification for international expansion and the need for strategic partnerships in unaddressed geographies.

StereoCED Potential: Rosa indicated that the StereoCED platform could be utilized in both clinical and preclinical stages, but adoption may be slow during ongoing clinical trials for existing therapies.

Trigeminal Neuralgia Product Strategy: The company plans to leverage existing personnel and distributors for the Trigeminal Nerve Ablation System while prioritizing the larger opportunity with the Brain Ablation devices. This summary encapsulates the key points from NMTC's Q3 2026 earnings call, highlighting both the company's progress and the challenges it faces as it moves forward.